Inicio › Leucemia linfocítica crónica › Carolina del Norte

Ensayos clínicos de Leucemia linfocítica crónica en Carolina del Norte

34 estudios sobre Leucemia linfocítica crónica buscan participantes en Carolina del Norte.

Ciudades en Carolina del Norte

Texto oficial del estudio (inglés)

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Southeastern Medical Oncology Center-Clinton, Clinton
Southeastern Medical Oncology Center-Goldsboro, Goldsboro
y 5 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT04269902

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Research Site, Charlotte
Research Site, Winston-Salem

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT06542250

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

GC2202 Study Site 109, Greenville
GC2202 Decentralized Study Site 114, Morrisville
GC2202 Study Site 117, Wilson

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT05645107

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

University of North Carolina At Chapel Hill, Chapel Hill
Levine Cancer Center, Charlotte
Atrium Health Wake Forest Baptist, Winston-Salem

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT06943872

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Atrium Health Levine Cancer Institute (Lci), Charlotte
Duke University Medical Center, Durham

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT07277231

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

University of North Carolina At Chapel Hill, Chapel Hill
Atrium Health Levine Cancer Institute (Lci), Charlotte
Duke University Medical Center, Durham
y 1 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT06973187

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Carolina Oncology Specialists, PA ( Site 0054), Charlotte
Southeastern Medical Oncology Center ( Site 0049), Goldsboro

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 24 sept 2026 · NCT06136559

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Duke University, Durham

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 21 sept 2026 · NCT07648264

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Duke University, Durham
Novant Health Cancer Institute, Winston-Salem

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT07221500

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 11 sept 2026 · NCT07061951

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

Research Site, Charlotte
Research Site, Charlotte

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT06564038

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

UNC School of Medicine, Division of Hematology, Chapel Hill

ReclutandoFase 1/2

Edades de 12 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT04588922

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Duke University Medical Center, Durham
Margaret R Pardee Memorial Hospital, Hendersonville

ReclutandoFase 3

Edades de 65 en adelante · Todos los sexos · Actualizado el 2 sept 2026 · NCT07321652

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

AdventHealth Infusion Center Asheville, Asheville
Southeastern Medical Oncology Center-Clinton, Clinton
AdventHealth Infusion Center Haywood, Clyde
y 6 más

ReclutandoEstudio observacionalSe aceptan voluntarios sanos

Edades de 40 a 75 · Todos los sexos · Actualizado el 2 sept 2026 · NCT05334069

Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

Research Site, Charlotte
Research Site, Durham
Research Site, Winston-Salem

ReclutandoFase 2

Edades de 18 a 130 · Todos los sexos · Actualizado el 6 ago 2026 · NCT07024706

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill

ReclutandoFase 1/2

Edades de 13 a 90 · Todos los sexos · Actualizado el 6 ago 2026 · NCT06533579

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

University of North Carolina at Chapel Hill, Chapel Hill

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 31 jul 2026 · NCT06708897

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Duke University Medical Center, Durham

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 jul 2026 · NCT05131022

Combating Cancer-Related Fatigue: A Personalized Supportive Care Program

North Carolina Basnight Cancer Hospital, Chapel Hill

Reclutando

Edades de 18 en adelante · Todos los sexos · Actualizado el 1 jul 2026 · NCT06860880

Registry of Older Patients With Cancer

Seby B. Jones Cancer Center, Boone
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
East Carolina University, Greenville
y 4 más

ReclutandoEstudio observacional

Edades de 65 en adelante · Todos los sexos · Actualizado el 29 jun 2026 · NCT01137825

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

East Carolina University, Greenville

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 19 may 2026 · NCT06588478

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

University of North Carolina, Chapel Hill

ReclutandoFase 1

Edades de 13 en adelante · Todos los sexos · Actualizado el 5 may 2026 · NCT04771572

The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

Wake Forest Baptist Health, Winston-Salem

ReclutandoEstudio observacional

Edades de 18 a 120 · Todos los sexos · Actualizado el 13 abr 2026 · NCT01890486

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Atrium Health /ID# 267219, Charlotte
Atrium Health Wake Forest Baptist Medical Center /ID# 273142, Winston-Salem

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 9 abr 2026 · NCT06428019

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Duke University Medical Center, Durham

ReclutandoFase 4

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 mar 2026 · NCT06876649

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Duke University Medical Center, Durham

ReclutandoFase 4

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 mar 2026 · NCT06876662

Study of SGR-1505 in Mature B-Cell Neoplasms

Duke University, Durham

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 13 feb 2026 · NCT05544019

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

University of North Carolina /ID# 233313, Chapel Hill
Novant Health Presbyterian Medical Center /ID# 230201, Charlotte
Novant Health Forsyth Medical Center /ID# 249533, Winston-Salem

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 9 feb 2026 · NCT04895436

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

The University of North Carolina at Chapel Hill, Chapel Hill

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 7 ene 2026 · NCT06043674

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Duke University, Durham

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 dic 2025 · NCT05602363

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill

ReclutandoEstudio observacional

Edades de 18 a 120 · Todos los sexos · Actualizado el 27 oct 2025 · NCT01137643

A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Durham VA Medical Center, Durham, NC, Durham

ReclutandoFase 2

Edades de 18 a 80 · Todos los sexos · Actualizado el 14 oct 2025 · NCT06520098

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

University of North Carolina, Chapel Hill

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 oct 2025 · NCT05780034

CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia

Duke University, Durham

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 17 jul 2025 · NCT04704323

De ClinicalTrials.gov, datos obtenidos el 1 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.